Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Biomarker Aids Risk Assessment of Sepsis

By LabMedica International staff writers
Posted on 25 Jan 2011
A clinical immunoassay enables rapid and accurate risk assessment of critically ill patients for severe sepsis and septic shock.

The assay is for Procalcitonin (PCT), a protein that can be used as a marker for sepsis caused by severe bacterial infections. More...
Unlike other sepsis biomarkers, it can be elevated much earlier in the condition.

Blood samples can be prepared and analyzed in just 19 minutes and patient results delivered one hour from taking the blood sample. In addition, levels of PCT in the human body correlate to the severity of the infection, enabling a more accurate and detailed assessment. The B.R.A.H.M.S. PCT assay (Thermo Fisher Scientific, Waltham, MA, USA) has made a significant contribution to clinical risk assessment in sepsis in critically ill patients when admitted to the ICU. At a decision making point of 2 ng/mL, PCT displayed a sensitivity of 99% and a specificity of 77% in differentiating patients on their first day of intensive care unit (ICU) admission with systemic inflammatory response syndrome (SIRS) and sepsis from those with severe sepsis and septic shock.

One of the main benefits of measuring PCT levels is that it is specific to severe bacterial infections, and does not rise in cases of viral infection. Therefore, application of PCT in Europe and the rest of the world have also been shown to predict accurately the absence of the condition early in the diagnosis stage, reducing costs and unnecessary antibiotic use. The PCT assay is already established in Europe, particularly Germany, France and Switzerland, where it has been used for risk assessment of sepsis in patients for more than ten years. The PCT received 510(k) clearance by the US Food and Drug Administration (FDA, Silver Spring, MD, USA), in April 2008.

Sepsis is characterized by a whole-body inflammatory state due to a systemic infection. In the US, incidence of sepsis is rising at an estimated 1.5% annually. Mortality rates range from 25% to nearly 50% and each hour of delay in therapy can decrease survival by 7.6%. Andy Thomson, president of Clinical Diagnostics at Thermo Fisher Scientific, said, "PCT has proven an effective tool for sepsis in Europe and is expected to become standard in the US as the industry learns more about its unique capabilities."

Related Links:

Thermo Fisher Scientific
FDA




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.